Drug Discovery Today

APRIL 7, 2020

OPENCORONA consortium awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak

Vaccine 100

Vaccine Research 100

The Pharma Data

DECEMBER 30, 2020

Becomes First Country to Approve Covid-19 Vaccine From Oxford-AstraZeneca. Britain became the first country to give authorization to the coronavirus vaccine developed by AstraZeneca and the University of Oxford, The New York Times reported Wednesday. © 2020 HealthDay. Posted: December 2020. All rights reserved.

Vaccine 52

Vaccine Pharmacy Clinical Trials Packaging 52

The Pharma Data

DECEMBER 21, 2020

military scientists to determine if it might be resistant to vaccines. The deal also includes more than $30 billion to acquire and distribute coronavirus vaccines and $27 billion for testing and state health care programs. Higher flu vaccination rates are one reason why flu cases are way down in the United States, experts say.

Vaccine 52

Vaccine Packaging Laboratories Virus 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

The Pharma Data

DECEMBER 18, 2020

Indigenous Communities Start Receiving COVID-19 Vaccines. 18, 2020 — Indigenous communities in the United States have started receiving COVID-19 vaccines from federal and state agencies. Other tribes will receive vaccine deliveries through state health agencies, the AP reported. © 2020 HealthDay. .

Vaccine 52

Vaccine Government 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. Moderna and Pfizer’s COVID-19 Vaccines Roll Out in Early Phase. Food and Drug Administration (FDA) issued Emergency Use Authorization for two COVID-19 vaccines: Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273. The duration of protection from the vaccines are not known yet.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

JANUARY 21, 2021

Percent of Kindergarteners Not Up to Date With MMR in 2019-2020. percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019 to 2020 school year, according to research published in the Jan. The researchers found that vaccination coverage was 94.9,

Vaccine 52

Vaccine Disease Research 52

The Pharma Data

DECEMBER 27, 2020

In 2020, messenger RNA (mRNA), the technology behind Pfizer’s and Moderna’s COVID-19 vaccine, practically became a household word. Now the gate is open for more mRNA vaccines to flood the space. Source link.

Vaccine 52

Vaccine RNA Research 52

Eye on FDA

MARCH 5, 2023

Note these numbers cover meetings about drug applications only, not including vaccines or cellular therapies. That said, beginning in 2020 meetings began skewing to more negative outcomes and 2022 was the first year where the number of negative outcomes outweighed the number of positive outcomes.

FDA 72

FDA Vaccine Drugs Therapies 72

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. © 2020 HealthDay. TUESDAY, Dec.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 — A second COVID-19 vaccine is poised to be administered in the coming weeks after the U.S. Food and Drug Administration granted emergency use authorization (EUA) to the Moderna COVID-19 vaccine on Friday. The EUA allows for the vaccine to be administered to adults 18 years and older in two doses one month apart.

Vaccine 52

Vaccine FDA Hospitals Disease 52

The Pharma Data

DECEMBER 30, 2020

Is First Country to Approve Oxford-AstraZeneca COVID-19 Vaccine. 30, 2020 — Britain became the first country to give authorization to the COVID-19 vaccine developed by AstraZeneca and the University of Oxford, The New York Times reported Wednesday. © 2020 HealthDay. Posted: December 2020. WEDNESDAY, Dec.

Vaccine 52

Vaccine Clinical Trials Government Regulations 52

The Pharma Data

DECEMBER 22, 2020

CanSino Biologics has enrolled more than 20,000 participants in a global phase 3 study of its COVID-19 vaccine candidate, Ad5-nCoV, co-developed with a research arm of the Chinese military. The adenovirus-based vaccine is one of five that China has progressed to phase 3 trials so far.

Vaccine 52

Vaccine Trials Pharmacy Research 52

The Pharma Data

DECEMBER 21, 2020

The Behavioural Insights Unit of the WHO released a meeting report of the Technical Advisory Group (TAG) on the special session on acceptance and uptake of COVID-19 vaccines, held on 15 October 2020. The discussion was structured around three key questions. Click here to download image in full size. . Source link.

Vaccine 52

Vaccine Science 52

The Pharma Data

DECEMBER 18, 2020

ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. © 2020 HealthDay. © 2020 HealthDay.

Vaccine 52

Vaccine Immune Response Treatment Drugs 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 02:44 UTC. Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. We look forward to vaccinations of this important population starting this week.”. CAMBRIDGE, Mass.–(

Vaccine 52

Vaccine Long-Term Care Facilities FDA Licensing 52

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan.

Vaccine 52

Vaccine Research Disease Drugs 52

The Pharma Data

JUNE 29, 2021

Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. “During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. . ” said Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur.

Vaccine 52

Vaccine Disease International Treatment 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

The Pharma Data

DECEMBER 20, 2020

Oxford University released new trial data last week that raises further questions about the most effective dosing regimen for Oxford’s COVID-19 vaccine candidate, AZD1222, that is being co-developed with AstraZeneca and how it came to pass that two different dosing regimens were pursued. AstraZeneca is leading the phase 3 U.S.

Vaccine 52

Vaccine Trials Regulations FDA 52

The Pharma Data

NOVEMBER 9, 2020

DAEGU, KOREA, November 09, 2020 /24-7PressRelease/ — South Korean religious group Shincheonji Church of Jesus has announced their third convalescent plasma donation drive to take place for 3 weeks starting November 16th at an Indoor Athletics Center in Daegu. Approximately 4,000 members of the group are expected to participate.

Treatment 145

Treatment Vaccine Disease 145

The Pharma Data

DECEMBER 30, 2020

30 December 2020 — AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. This is the first authorisation for this vaccine.

Vaccine 52

Vaccine Clinical Trials Trials Virus 52

The Pharma Data

MAY 13, 2021

Product Name: 2020 New Weight Loss Offer! Click here to get 2020 New Weight Loss Offer! 2020 New Weight Loss Offer! Description: Click here to get 2020 New Weight Loss Offer! 2020 New Weight Loss Offer! is backed with a 60 Day No Questions Asked Money Back Guarantee.

Production 52

Production Vaccine 52

The Pharma Data

DECEMBER 19, 2020

20, 2020 11:00 UTC. government’s public-private partnership to deliver COVID-19 vaccines to Americans, and under the direction of the Centers for Disease Control and Prevention (CDC) , McKesson began distributing Moderna’s COVID-19 vaccines and the ancillary supply kits needed to administer them. 21, 2020.

Government 52

Government Vaccine Pharmacy Pharmaceuticals 52

The Pharma Data

JULY 15, 2021

FreVAX is an innovative intramuscular needle free vaccine injection device for pigs around weaning until the end of nursery. FreVAX intramuscular needle free device has been available since December 2020 to swine producers globally. billion euros in 2020 and presence in more than 150 countries. The FreVAX app 2.0

Vaccine 52

Vaccine Compliance Disease 52

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021. We look forward to sharing initial results by year-end. ”. “

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

DrugBaron

NOVEMBER 9, 2020

The first death unequivocally caused by COVID was reported to the world on January 11 th 2020 – that’s just 303 days ago (even if it feels like a lifetime away). Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

The Pharma Data

JANUARY 11, 2021

Queen Elizabeth II and her husband, Prince Philip received COVID-19 vaccinations on Saturday, according to Buckingham Palace officials. The 94-year-old monarch and her husband, 99, received their first vaccine dose at Windsor Castle, where they’ve remained during the lockdown in England, CBS News reported. © 2021 HealthDay.

Virus 52

Virus Vaccine FDA Research 52

The Pharma Data

JANUARY 25, 2021

In a surprise move, Merck announced that it is giving up on its two coronavirus vaccine candidates after seeing a subpar immune response and shifting its focus to a pair of investigational coronavirus treatments. 24, 2020 ). 28, 2020 ). The drugmaker’s decision coincides with a tightening of vaccine supplies in the U.S.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

DECEMBER 23, 2020

With news of a new Covid-19 variant spreading more rapidly than the original version in the UK, Pharma IQ has selected four updates that came out of the pharma industry in 2020, so you can begin the New Year with innovative solutions and research options to transform your pharma strategies for 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials FDA 52

The Pharma Data

SEPTEMBER 5, 2021

million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines. “The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. The study reported findings from mid-December 2020 through June 26, 2021. The total number of people evaluated was 6.2

Vaccine 52

Vaccine Clinical Trials Research Virus 52

The Pharma Data

JANUARY 29, 2021

Adults Want the COVID-19 Vaccine as Soon as Possible. adults are increasingly eager to get the COVID-19 vaccine, according to survey results released by the Kaiser Family Foundation (KFF) COVID-19 Vaccine Monitor. 8, 2020, and included a nationally representative random-digit dial telephone sample of 1,676 adults.

Vaccine 52

Vaccine 52

The Pharma Data

JANUARY 6, 2021

6 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunisation of adults. Additional safety and efficacy data will continue to accumulate from ongoing clinical trials.

Vaccine 52

Vaccine Virus Clinical Trials Trials 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

The Pharma Data

MARCH 8, 2021

Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. As announced in December 2020 1 , VLA15-221 is a randomized, observer-blind, placebo-controlled Phase 2 study. We are excited to be part of the Lyme disease vaccine development program with Valneva.

Vaccine 52

Vaccine Disease Protein Expression Trials 52